# Capricor Therapeutics Inc. (CAPR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.40, market value $547 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Capricor Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.2×**. The shares trade at 2.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -21.0%** (5-yr avg -11.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -34.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -29.5%**. Each dollar of assets produces -29.5% of profit.

## Growth
- **Revenue growth (1 yr): -100.0%** (3-yr -100.0%/yr, 5-yr -100.0%/yr). Revenue fell 100.0% over the last year, against -100.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -96.5%**. Earnings per share fell 96.5%, roughly in step with revenue.

## Financial health
- **Current ratio: 9.01** (quick 9.01). Current assets cover the next year's liabilities 9.01 times.
- **Altman Z-score: 7.71**. A Z-score of 7.71 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Capricor Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (4 analysts). 4 analysts cover Capricor Therapeutics Inc.; the consensus is hold, with an average price target of $22.75 (+142% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 58.2%** (YTD -67.4%, 3-mo -64.8%). The shares are up 58.2% over twelve months including dividends.
- **From 52-week high: -76.7%** (217.6% above the low). Trading 77% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 0.91** (volatility 393%). Beta of 0.91 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CAPR · Page: https://foliofundamentals.com/stocks/capr

Not investment advice.